6.
Sormanni P, Aprile F, Vendruscolo M
. The CamSol method of rational design of protein mutants with enhanced solubility. J Mol Biol. 2014; 427(2):478-90.
DOI: 10.1016/j.jmb.2014.09.026.
View
7.
Blanchard P, Knick B, Whelan S, Hackel B
. Hyperstable Synthetic Mini-Proteins as Effective Ligand Scaffolds. ACS Synth Biol. 2023; 12(12):3608-3622.
PMC: 10822706.
DOI: 10.1021/acssynbio.3c00409.
View
8.
Hackel B, Ackerman M, Howland S, Wittrup K
. Stability and CDR composition biases enrich binder functionality landscapes. J Mol Biol. 2010; 401(1):84-96.
PMC: 3927142.
DOI: 10.1016/j.jmb.2010.06.004.
View
9.
Grinshpun B, Thorsteinson N, Pereira J, Rippmann F, Nannemann D, Sood V
. Identifying biophysical assays and properties that enrich for slow clearance in clinical-stage therapeutic antibodies. MAbs. 2021; 13(1):1932230.
PMC: 8204999.
DOI: 10.1080/19420862.2021.1932230.
View
10.
Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu T
. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013; 26(10):663-70.
DOI: 10.1093/protein/gzt047.
View
11.
Galarneau A, Primeau M, Trudeau L, Michnick S
. Beta-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein protein interactions. Nat Biotechnol. 2002; 20(6):619-22.
DOI: 10.1038/nbt0602-619.
View
12.
Jain T, Boland T, Vasquez M
. Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches. MAbs. 2023; 15(1):2200540.
PMC: 10114995.
DOI: 10.1080/19420862.2023.2200540.
View
13.
Bailly M, Mieczkowski C, Juan V, Metwally E, Tomazela D, Baker J
. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening. MAbs. 2020; 12(1):1743053.
PMC: 7153844.
DOI: 10.1080/19420862.2020.1743053.
View
14.
Cabantous S, Waldo G
. In vivo and in vitro protein solubility assays using split GFP. Nat Methods. 2006; 3(10):845-54.
DOI: 10.1038/nmeth932.
View
15.
Gebauer M, Skerra A
. Engineered Protein Scaffolds as Next-Generation Therapeutics. Annu Rev Pharmacol Toxicol. 2020; 60:391-415.
DOI: 10.1146/annurev-pharmtox-010818-021118.
View
16.
Velikyan I, Schweighofer P, Feldwisch J, Seemann J, Frejd F, Lindman H
. Diagnostic HER2-binding radiopharmaceutical, [Ga]Ga-ABY-025, for routine clinical use in breast cancer patients. Am J Nucl Med Mol Imaging. 2019; 9(1):12-23.
PMC: 6420710.
View
17.
McConnell A, Batten S, Hackel B
. Determinants of Developability and Evolvability of Synthetic Miniproteins as Ligand Scaffolds. J Mol Biol. 2023; 435(24):168339.
PMC: 10872777.
DOI: 10.1016/j.jmb.2023.168339.
View
18.
Klesmith J, Su L, Wu L, Schrack I, Dufort F, Birt A
. Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins. Mol Pharm. 2019; 16(8):3544-3558.
DOI: 10.1021/acs.molpharmaceut.9b00418.
View
19.
Tian G, Tang F, Yang C, Zhang W, Bergquist J, Wang B
. Quantitative dot blot analysis (QDB), a versatile high throughput immunoblot method. Oncotarget. 2017; 8(35):58553-58562.
PMC: 5601674.
DOI: 10.18632/oncotarget.17236.
View
20.
Lown P, Cai J, Ritter S, Otolski J, Wong R, Hackel B
. Extended yeast surface display linkers enhance the enrichment of ligands in direct mammalian cell selections. Protein Eng Des Sel. 2021; 34.
PMC: 8058008.
DOI: 10.1093/protein/gzab004.
View